PATENT CLAIM ANALYSIS

Application Number: 16304564
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-06
Patent Classification: ["424", "232100"]

Abstract:
Methods utilizing vaccinia virus with mutations in E3L to infect and cause lysis of cancer cells with less than normal protein levels of RIP3 and/or DAI. Further, the disclosed vaccinia viruses with mutations in E3L cannot replicate well in cells with normal expression or upregulation of RIP3, DAI, and/or MLKL.

Claim (Index 16):
A pharmaceutical composition of treating a cancer, comprising a vaccinia virus (VACV) having a mutation in an E3L gene of said virus and a pharmaceutically acceptable carrier.

Metadata:
- Claim Count in Document: 44.0
- Percentile: 98.0
- Lexical Diversity: 1.47368
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14166606', '15758689', '13383396', '13060028', '13147842']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7203852334095057
- 35 USC 102 Novelty (BERT): 0.5074621745974706
- Combined Prediction Score: 0.6990929275283022
- Mean Citation Score: 256.83684600000004
- Max Citation Score: 270.8731
- Similarity Product: 187.1910355006099

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test